Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Micro Cap & Branchenriese: Heute rein? - Partnerschaft entfacht Übernahmefantasien!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
472 Leser
Artikel bewerten:
(1)

Web Presence: Kristopher Kale Sligh on why Some Marketers Fail in the Industry

Finanznachrichten News

Marketing is both a lucrative and a rewarding career for the right person. However, not every marketer is going to achieve success. Kristopher Kale Sligh explains why that is.

FRANKLIN, TN / ACCESSWIRE / March 24, 2020 / So you want to be a marketer then? That's great to hear! There are a lot of opportunities and directions that you can take in this industry, and if you are both ambitious and skilled enough, you can find a lot of success in it. However, that is not to say that it is all sunshine and rainbows. It is, after all, a career, not a game, which means that if you make the wrong decisions in it, you can very quickly find yourself failing in it. Kristopher Kale Sligh explains the things to avoid if you want to have a long, fulfilling career.

Kristopher Kale Sligh: Things marketers do that do them in

Marketing a product, person, company, what have you, can be a delicate balancing act. One mistake can, if you are not careful, throw a wrench into the whole operation, Kristopher Kale Sligh points out. All too many marketers, unfortunately, do not think about what their goal is. Money is also a frequent smoking gun for a failed marketer or marketing campaign in various different ways. It can be due to not properly budgeting your campaign properly (or even at all), or it can be that you underestimated how much money a campaign will ultimately cost you. If you are a marketer with a high degree of significance, Kristopher Kale Sligh explains, you may not have to worry as much about taking a financial hit due to a mix up with the budget, but at the same time, overspending or failing to properly plan your budget can create a negative reputation for you and your marketing firm, such that companies may be reticent to work with you. Even if you are exceptional in other ways, companies tend not to like it when their marketing campaigns cost them more money than you told them, Kristopher Kale Sligh points out.

Perhaps the biggest thing that does marketers in, Kristopher Kale Sligh explains, is not thinking about why they failed in the past. Failure is not necessary to be a good marketer, but it is certainly helpful knowledge. After all, once you fail, you suddenly have knowledge of what not to do, right? Like pretty much all marketers, Kristopher Kale Sligh has skinned his knee more than once, but learning caution and figuring out why you skinned your knee can make a huge impact on your future career. It is a thing that Kristopher Kale Sligh has not forgotten and certainly will not. So, when you do inevitably fail, don't feel like it's the end of your career. Pick yourself up, dust yourself off, and keep going to where you want to be in your life.

CONTACT:

Caroline Hunter
Web Presence, LLC
+1 7865519491

SOURCE: Web Presence, LLC



View source version on accesswire.com:
https://www.accesswire.com/582176/Kristopher-Kale-Sligh-on-why-Some-Marketers-Fail-in-the-Industry

© 2020 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.